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In the present study, some novel ferrocene derivatives carrying urea, thiourea, and sulfonamide groups were synthesized, and all
compoundswerecharacterizedbyspectralandelementalanalyses.Thesecompoundswerescreenedfortheirantibacterialactivities
andalsotheirminimuminhibitoryconcentration(MIC)againstGram-positivebacteria(StaphylococcusaureusandBacillussubtilis)
and Gram-negative bacteria (Klebsiella pneumonia and Escherichia coli) and antifungal activities against Saccharomyces cerevisiae
and Candida albicans. Amongst the tested compounds, 4b, 4c, 5b,a n d6b displayed excellent antimicrobial activity.
1. Introduction
Althoughthere are manyimportantdevelopmentsin antimi-
crobial therapy infectious diseases caused by bacteria and
fungi remain a major global health problem because of the
rapid development of resistance to the existing antimicrobial
drugs, in other words, the increasing use and misuse of the
existingantimicrobialdrugshaveresultedinthedevelopment
of resistant pathogens [1–3]. Therefore, novel antimicrobial
agents are needed for effective treatment against infections
caused by the pathogenic microbes.
Ferrocene and its derivatives find extensive applications
in areas like homogeneous catalysis, material science, non-
linear optics, and molecular sensors [4–10]. Additionally,
incorporation of a ferrocene fragment into a molecule of
an organic compound often produces unexpected biological
activity. Recently, some new ferrocenyl-substituted organic
compounds as potential pharmaceuticals have been reported
[11–15].Manyferrocenylcompoundsdisplayinterestingcyto-
toxic, antitumor, antimalarial, antifungal, antioxidant, and
DNA-cleaving activity [16–18].
Inaddition,someurea,thiourea,andsulfonamidederiva-
t i v e sa r ek n o w nt ob ea s s o c i a t e dw i t haw i d er a n g eo f
biologicalactivitiessuchasanalgesic,antitumor,antioxidant,
anticonvulsant, and anti-HIV properties [19–28]. However,
antibacterial and antifungal activities of urea and thiourea
derivatives have been less widely documented [29, 30]. In
view of the above-mentioned facts and in an attempt to
achieve potential antibacterial and antifungal agents, in the
present study we hereby report the synthesis of some ferro-
cenyl substituted urea, thiourea, and sulfonamide derivatives
and evaluation of their in vitro antimicrobial activities.
The structural characterization and preliminary biological
evaluation of these novel compounds could be interesting for
screening potent drug.
2. Experimental
All the reagents for syntheses were commercially available
a n du sedwi th o u tfurth erp urifica tio no rp urifiedb ys ta n da r d
methods prior to use. Melting points were determined using
an Electrothermal 9100 apparatus, uncorrected. All NMR
spectra were recorded on a Bruker 400 (
1H: 400MHz,
13C:
100MHz) NMR spectrometer, in CDCl3.C h e m i c a ls h i ft
values were reported in ppm relative to those for TMS used
as an internal reference standard, J in Hz. The elemental
a n a l y s e sf o rC ,H ,N ,a n dSw e r ed o n eo nL E C O ,C H N S - 9 3 2 .
FTIR spectra were recorded on a Mattson 1000 spectrometer2 Journal of Chemistry
using KBr pellets. The progress of reactions was monitored
by TLC using Silufol UV-254 plates. The compounds 2 and 3
were synthesized using a published method. All the physical
and spectral data were in line with the previously reported
results [31, 32].
2.1. General Procedure for Synthesis of (4a–4e). As t i r r e d
mixtureof4-ferrocenylaniline(3,2.77g,10mmol)andamol-
equivalentamountofthecorrespondingphenylisocyanatein
20mLethanolisheatedunderrefluxfor2h(TLCcontrol).At
the end of this period, the reaction mixture was evaporated
to dryness. This crude product was recrystallized from an
appropriate solvent to afford the desired compound.
2.1.1. 1-(4-Ferrocenylphenyl)-3-phenylurea (4a). Crystalliza-
tion from ethanol; orange powder, 83% yield; mp 181-182
∘C;
IR (],c m
−1): 3054, 1639, 1611.
1H-NMR (400 MHz, CDCl3):
10.85(1H,s,NH),9 .51(1H,s,NH),7 .82(2H,d,J =8.6Hz,Ar –
H ) ,7 . 5 6( 2 H ,d ,J = 8.6 Hz, Ar–H), 6.97–7.48 (5H, m, Ar–H),
5.01(2H,s,C5H4),4.48(2H,s,C5H4),4.02(5H,s,C5H5).
13C-
NMR (100MHz, CDCl3): 64.3, 68.7, 69.4, 86.1, 121.3, 122.0,
128.3, 129.1, 131.6, 133.9, 138.4, 140.2, 156.4. Elemental analysis
for C23H20FeN2O :C a l c u l a t e d :C ,6 9 . 7 1 ;H ,5 . 0 9 ;N ,7 . 0 7 % .
Found: C, 69.81; H, 5.01; N, 7.19%.
2.1.2. 1-(4-Chlorophenyl)-3-(4-ferrocenylphenyl)urea (4b).
Crystallization from ethanol; yellow powder, 87% yield;
mp 166-167
∘C; IR (],c m
−1): 3067, 1632, 1604.
1H-NMR
(400MHz, CDCl3) :1 0 . 9 3( 1 H ,s ,N H ) ,9 . 4 3( 1 H ,s ,N H ) ,7 . 7 3
(2H, d, J =8 . 4H z ,A r – H ) ,7 . 5 9( 2 H ,d ,J =8 . 0H z ,A r – H ) ,7 . 5 6
(2H, d, J = 8.4Hz, Ar–H), 7.45 (2H, d, J =8 . 0H z ,A r – H ) ,
4.93 (2H, s, C5H4), 4.45 (2H, s, C5H4), 4.01 (5H, s, C5H5).
13C-NMR (100MHz, CDCl3): 65.9, 69.3, 70.7, 87.2, 115.9,
122.5, 127.1, 129.0, 135.5, 139.2, 139.9, 141.1, 156.1. Elemental
analysis for C23H19ClFeN2O :C a l c u l a t e d :C ,6 4 . 1 4 ;H ,4 . 4 5 ;
N, 6.50%. Found: C, 64.04; H, 4.41; N, 6.45%.
2.1.3. 1-(4-Bromophenyl)-3-(4-ferrocenylphenyl)urea (4c).
Crystallization from butanol; yellow powder, 80% yield;
mp 201-202
∘C; IR (],c m
−1): 3084, 1629, 1601.
1H-NMR
(400MHz, CDCl3) :1 0 . 7 3( 1 H ,s ,N H ) ,9 . 6 2( 1 H ,s ,N H ) ,7 . 9 2
(2H, d, J =8 . 3H z ,A r – H ) ,7 . 6 1( 2 H ,d ,J =8 . 3H z ,A r – H ) ,7 . 5 4
(2H, d, J = 8.6Hz, Ar–H), 7.46 (2H, d, J =8 . 6H z ,A r – H ) ,
4.96 (2H, s, C5H4), 4.44 (2H, s, C5H4), 4.02 (5H, s, C5H5).
13C-NMR (100MHz, CDCl3): 64.3, 69.0, 69.5, 86.3, 118.4,
121.6, 122.1, 124.9, 135.3, 139.0, 139.4, 141.3, 155.0. Elemental
analysis for C23H19BrFeN2O :C a l c u l a t e d :C ,5 8 . 1 4 ;H ,4 . 0 3 ;
N, 5.90%. Found: C, 58.04; H, 4.00; N, 6.02%.
2.1.4. 1-(4-Ferrocenylphenyl)-3-p-tolylurea (4d). Crystalliza-
tion from ethanol; orange powder, 74% yield; mp 146-147
∘C;
IR (],c m
−1): 3053, 2987, 1632, 1609.
1H-NMR (400MHz,
CDCl3) :1 0 . 8 4( 1 H ,s ,N H ) ,9 . 4 9( 1 H ,s ,N H ) ,7 . 8 0( 2 H ,d ,J
=8 . 5H z ,A r – H ) ,7 . 5 5( 2 H ,d ,J = 8.5 Hz, Ar–H), 7.30 (2H, d,
J =8 . 2H z ,A r – H ) ,7 . 1 1( 2 H ,d ,J = 8.2Hz, Ar–H), 4.94 (2H,
s, C5H4), 4.45 (2H, s, C5H4), 4.01 (5H, s, C5H5), 2.32 (3H,
s, CH3).
13C-NMR (100MHz, CDCl3): 22.2, 64.1, 68.8, 69.3,
86.0, 118.1, 119.3, 124.8, 127.6, 133.2, 136.9, 138.8, 141.2, 155.8.
ElementalanalysisforC24H22FeN2O:Calculated:C,70.26;H,
5 . 4 0 ;N ,6 . 8 3 % .F o u n d :C ,7 0 . 3 4 ;H ,5 . 4 6 ;N ,6 . 7 5 % .
2.1.5. 1-(4-Ferrocenylphenyl)-3-(4-methoxyphenyl)urea (4e).
Crystallization from ethanol; orange powder, 86% yield; mp
173-174
∘C; IR (],c m
−1): 3078, 2993, 1639, 1612.
1H-NMR
(400MHz, CDCl3) :1 0 . 9 1( 1 H ,s ,N H ) ,9 . 4 3( 1 H ,s ,N H ) ,7 . 8 4
(2H, d, J =8 . 4H z ,A r – H ) ,7 . 6 0( 2 H ,d ,J =8 . 4H z ,A r – H ) ,
7.50 (2H, d, J =8 . 9H z ,A r – H ) ,9 . 9 3( 2 H ,d ,J =8 . 9H z ,A r – H ) ,
4.96 (2H, s, C5H4), 4.43 (2H, s, C5H4), 4.02 (5H, s, C5H5),
3.32 (3H, s, OCH3).
13C-NMR (100MHz, CDCl3): 55.2, 64.4,
69.0,69.6,86.1,113.2,118.3,119.9,124.6,130.0,138.8,141.1,154.2,
155.9. Elemental analysis for C24H22FeN2O2:C a l c u l a t e d :C ,
67.62; H, 5.20; N, 6.57%. Found: C, 67.55; H, 5.12; N, 6.49%.
2.2. General Procedure for Synthesis of (5a–5e). As t i r r e d
mixture of 4-ferrocenylaniline (2.77g, 10mmol) and a mol-
equivalentamountofthecorrespondingphenylisocyanatein
20mLethanolisheatedunderrefluxfor2h(TLCcontrol).At
the end of this period, the reaction mixture was evaporated
to dryness. This crude product was recrystallized from an
appropriate solvent to afford the desired compound.
2.2.1. 1-(4-Ferrocenylphenyl)-3-phenylthiourea (5a). Crystal-
lization from methanol; brown powder, 79% yield; mp 167-
168
∘C;IR(],cm
−1):3072.
1H-NMR(400MHz,CDCl 3):10.93
(1H, s, NH), 9.82 (1H, s, NH), 7.20-7.73 (7H, m, Ar–H), 6.80
(2H, d, J =8 . 6H z ,A r – H ) ,5 . 0 2( 2 H ,s ,C 5H4), 4.47 (2H,
s, C5H4), 4.00 (5H, s, C5H5).
13C-NMR (100MHz, CDCl3):
63.7, 68.7, 69.3, 85.5, 119.7, 122.6, 124.3, 127.7, 130.3, 138.1, 138.4,
143.2, 180.2. Elemental analysis for C23H20FeN2S: Calculated:
C, 67.00; H, 4.89; N, 6.79; S, 7.78%. Found: C, 66.91; H, 4.84;
N, 6.73; S 7.64%.
2.2.2. 1-(4-Chlorophenyl)-3-(4-ferrocenylphenyl)thiourea (5b).
Crystallization from butanol; yellow powder, 81% yield; mp
157-158
∘C; IR (],c m
−1): 3081.
1H-NMR (400MHz, CDCl3):
11.01 (1H, s, NH), 9.85 (1H, s, NH), 7.67 (2H, d, J =8 . 5H z ,
Ar–H), 7.16 (2H, d, J =8 . 2 H z ,A r – H ) ,6 . 9 3( 2 H ,d ,J =
8.5Hz, Ar–H), 6.69 (2H, d, J =8 . 2H z ,A r – H ) ,5 . 0 3( 2 H ,s ,
C5H4), 4.49 (2H, s, C5H4), 4.04 (5H, s, C5H5).
13C-NMR
(100MHz, CDCl3): 63.9, 68.6, 69.4, 85.9, 119.5, 122.5, 124.3,
127.7, 130.3, 138.1, 138.3, 143.2, 179.2. Elemental analysis for
C23H19ClFeN2S :C a l c u l a t e d :C ,6 1 . 8 3 ;H ,4 . 2 9 ;N ,6 . 2 7 ;S ,
7.18%. Found: C, 61.96; H, 4.25; N, 6.24; S, 7.10%.
2.2.3. 1-(4-Bromophenyl)-3-(4-ferrocenylphenyl)thiourea (5c).
Crystallization from ethanol; orange powder, 89% yield; mp
189-190
∘C; IR (],c m
−1): 3046.
1H-NMR (400MHz, CDCl3):
11.03 (s, 1H, NH), 9.94 (s, 1H, NH), 7.70 (2H, d, J =8 . 5H z ,
Ar–H), 7.42 (2H, d, J = 8.8Hz, Ar–H), 6.92 (2H, d, J =
8.5Hz, Ar–H), 6.73 (2H, d, J =8 . 8H z ,A r – H ) ,5 . 0 3( 2 H ,s ,
C5H4), 4.47 (2H, s, C5H4), 4.01 (5H, s, C5H5).
13C-NMR
(100MHz, CDCl3): 64.2, 68.9, 69.7, 86.3, 117.3, 122.1, 125.2,
132.8, 133.5, 137.2, 139.4, 140.3, 179.3. Elemental analysis forJournal of Chemistry 3
C23H19BrFeN2S :C a l c u l a t e d :C ,5 6 . 2 4 ;H ,3 . 9 0 ;N ,5 . 7 0 ;S ,
6.53%. Found: C, 56.14; H, 3.83; N, 5.63; S, 6.45%.
2.2.4. 1-(4-Ferrocenylphenyl)-3-p-tolylthiourea (5d). Crystal-
lizationfromethanol;brownpowder,80%yield;mp111-112
∘C;
IR (],c m
−1): 3061.
1H - N M R( 400M H z ,C DCl 3): 10.95 (1H, s,
NH), 9.86 (1H, s, NH), 7.65 (2H, d, J = 8.6Hz, Ar–H), 7.02
(2H, d, J =8 . 3H z ,A r – H ) ,6 . 8 8( 2 H ,d ,J =8 . 6H z ,A r – H ) ,
6.79 (2H, d, J =8 . 3H z ,A r – H ) ,5 . 0 4( 2 H ,s ,C 5H4), 4.45 (2H,
s, C5H4), 4.02 (5H, s, C5H5), 2.27 (3H, s, CH3).
13C-NMR
(100MHz,CDCl3):21.5,63.9,68.6,69.6,85.8,117.8,123.7,127.2,
133.4, 135.1, 138.8, 139.6, 142.5, 180.5. Elemental analysis for
C24H22FeN2S :C a l c u l a t e d :C ,6 7 . 6 1 ;H ,5 . 2 0 ;N ,6 . 5 7 ;S ,7 . 5 2 % .
Found: C, 67.46; H, 5.14; N, 6.49; S, 7.41%.
2.2.5. 1-(4-Ferrocenylphenyl)-3-(4-methoxyphenyl)thiourea
(5e). Crystallization from butanol; brown powder, 83%
yield; mp 182-183
∘C; IR (],c m
−1): 3059.
1H-NMR (400MHz,
CDCl3) :1 0 . 9 2( 1 H ,s ,N H ) ,9 . 8 3( 1 H ,s ,N H ) ,7 . 7 2( 2 H ,d ,J =
8.4 Hz, Ar–H), 6.89 (2H, d, J = 8.4Hz, Ar–H), 6.83 (2H, d,
J = 8.8Hz, Ar–H), 6.77 (2H, d, J =8 . 8H z ,A r – H ) ,5 . 0 2( 2 H ,
s, C5H4), 4.43 (2H, s, C5H4), 4.01 (5H, s, C5H5), 3.21 (3H, s,
OCH3).
13C-NMR (100MHz, CDCl3): 53.2, 64.2, 68.8, 69.7,
85.9, 114.6, 118.2, 122.2, 125.3, 132.1, 139.3, 141.5, 155.3, 179.7.
Elemental analysis for C24H22FeN2OS: Calculated: C, 65.16;
H, 5.01; N, 6.33; S, 7.25%. Found: C, 65.10; H, 5.03; N, 6.26; S,
7.33%.
2.3. General Procedure for Synthesis of (6a–6d). Am i x t u r eo f
4-ferrocenylaniline (2.77g, 10mmol), dicyclohexylcarbodi-
imide (2.06g, 10mmol DCC), and 4-N,N
򸀠-dimethylami-
nopyridine (1.22g, 10mmol DMAP) in dichloromethane
was stirred at 0
∘C for 3h. Then the corresponding sulfonic
acid derivatives were added to the mixture. After 2h, the
temperature of the solution was allowed to increase to
room temperature, and the solution was stirred at this
temperature for 12h. The precipitatedN,N
򸀠-dicyclohexylurea
was removed by filtration, with the filtrate being extracted
with 10% NaHCO3.Th eo r g a n i cp h a s ee v a p o r a t e d ,a n dt h e
precipitate that occurred was filtrated and crystallized from
an appropriate solvent to afford the desired compound.
2.3.1. N-(4-Ferrocenylphenyl)methanesulfonamide (6a).
Crystallization from methanol; yellow powder, 71% yield;
mp 109-110
∘C; IR (],c m
−1): 3039, 2983, 1613, 1030.
1H-NMR
(400MHz, CDCl3): 11.34 (1H, s, NH), 7.22 (2H, d, J =8 . 4H z ,
Ar–H), 6.97 (2H, d, J =8 . 4H z ,A r – H ) ,4 . 9 6( 2 H ,s ,C 5H4),
4.39 (2H, s, C5H4), 4.04 (5H, s, C5H5), 3.22 (3H, s, CH3).
13C-NMR(100MHz,CDCl3):34.6,67.2,70.1,70.4,84.3,114.3,
127.1, 129.6, 138.4. Elemental analysis for C17H17FeNO2S:
C a l c u l a t e d :C ,5 7 . 4 8 ;H ,4 . 8 2 ;N ,3 . 9 4 ;S ,9 . 0 3 % .F o u n d :C ,
57.41; H, 4.89; N, 3.85; S, 9.11%.
2.3.2. N-(4-Ferrocenylphenyl)ethanesulfonamide (6b). Crys-
tallization from methanol; yellow powder, 74% yield; mp
132-133
∘C; IR (],c m
−1) :3 0 5 6 ,2 9 8 9 ,1 6 1 9 ,1 0 2 3 .
1H-NMR
(400MHz, CDCl3): 11.23 (1H, s, NH), 7.45 (2H, d, J =8 . 4H z ,
Ar–H), 6.81 (2H, d, J =8 . 4H z ,A r – H ) ,5 . 0 1( 2 H ,s ,C 5H4),
4.42 (2H, s, C5H4), 4.01 (5H, s, C5H5), 3.40 (2H, q, J =7 . 6H z ,
CH2), 1.52 (3H, t, J =7 . 6H z ,C H 3).
13C-NMR (100MHz,
CDCl3):23.1,48.3,67.6,70.2,70.5,84.5,119.7,128.5,133.9,137.5.
Elemental analysis for C18H19FeNO2S :C a l c u l a t e d :C ,5 8 . 5 5 ;
H, 5.19; N, 3.79; S, 8.68%. Found: C, 58.69; H, 5.16; N, 3.71; S,
8.56%.
2.3.3.N-(4-Ferrocenylphenyl)benzenesulfonamide(6c). Crys-
tallization from ethanol; orange powder, 68% yield; mp 174-
175
∘C; IR (],c m
−1): 3087, 1612, 1015.
1H-NMR (400MHz,
CDCl3): 11.31 (1H, s, NH), 7.25–7.61 (7H, m, Ar–H), 6.96 (2H,
d, J = 8.6Hz, Ar–H), 4.94 (2H, s, C5H4), 4.40 (2H, s, C5H4),
4.03 (5H, s, C5H5).
13C-NMR (100MHz, CDCl3): 67.4, 70.1,
70.4,84.2,119.3,125.1,127.4,121.1,133.4,134.2,140.9.Elemental
analysis for C22H19FeNO2S :C a l c u l a t e d :C ,6 3 . 3 2 ;H ,4 . 5 9 ;N ,
3.36; S, 7.68%. Found: C, 63.24; H, 4.52; N, 3.69; S, 7.75%.
2.3.4. N-(4-Ferrocenylphenyl)-4-methylbenzensulfonamide
(6d). Crystallization from ethanol; yellow powder, 68%
yield; mp 169-170
∘C; IR (],c m
−1): 3045, 2986, 1621, 1017.
1H-NMR (400MHz, CDCl3): 11.27 (1H, s, NH), 7.81 (2H, d,
J =8 . 2H z ,A r – H ) ,7 . 5 2( 2 H ,d ,J = 8.5Hz, Ar–H), 7.28 (2H,
d, J = 8.2Hz, Ar–H), 7.01 (2H, d, J =8 . 5 H z ,A r – H ) ,4 . 7 0
(2H, s, C5H4), 4.41 (2H, s, C5H4), 4.02 (5H, s, C5H5), 2.26
(3H, CH3).
13C-NMR (100MHz, CDCl3): 24.3, 67.2, 69.4,
70.3, 84.4, 117.7, 122.6, 126.5, 128.2, 137.3, 137.4, 138.8, 140.4.
Elemental analysis for C23H21FeNO2S: Calculated: C, 64.05;
H, 4.91; N, 3.25; S, 7.43%. Found: C, 64.14; H, 4.82; N, 3.19; S,
7.32%.
3. Antimicrobial Evaluation
Chemicalcompoundswereindividuallytestedagainstapanel
of Gram-positive and Gram-negative bacterial pathogens,
yeast, and fungi. Antimicrobial tests were carried out by the
agar well diffusion method [33]u s i n g1 0 0𝜇Lo fs u s p e n s i o n
containing 1×1 0
6 CFU/mL of pathological tested bacteria
and 1×1 0
6/mL of yeast spread on nutrient agar (NA)
and Sabouraud dextrose agar (SDA), respectively. After the
media had cooled and solidified, wells (10mm in diameter)
were made in the solidified agar and loaded with 100𝜇Lo f
tested compound solution prepared by dissolving 100mg of
the chemical compound in one mL of dimethyl sulfoxide
( D M S O ) .Th ei n c u l c a t e dp l a t e sw e r et h e ni n c u b a t e df o r2 4h
at 37
∘Cf o rb a c t e r i aa n d4 8 ha t2 8
∘C for fungi. Negative
controlswere preparedusing DMSO employed fordissolving
the tested compound. Ciprofloxacin (50𝜇g/mL) and Keto-
conazole (50𝜇g/mL) were used as standard for antibacterial
and antifungal activities respectively. After incubation time,
antimicrobial activity was evaluated by measuring the zone
of inhibition against the test organisms and compared with
that of the standard. Antimicrobial activities were expressed
as inhibition diameter zones in millimeters (mm). The
experimentwascarriedoutintriplicate,andtheaveragezone
of inhibition was calculated. Compounds that showed sig-
nificant growth inhibition zones (>14mm) using the twofold4 Journal of Chemistry
serial dilution technique were further evaluated for their
minimal inhibitory concentrations (MIC).
3.1. Minimal Inhibitory Concentration (MIC) Measurement.
ThemicrodilutionsusceptibilitytestinM¨ uellerHintonBroth
(Oxoid) was used for the determination of antibacterial
activity, and Sabouraud Liquid Medium (Oxoid) was used
for the determination of antifungal activity. Stock solutions
of the tested compounds, Ciprofloxacin, and Ketoconazole
were prepared in DMF at concentration of 1000mg/mL.
Twofold serial dilutions of the tested compounds solutions
were prepared using the proper nutrient broth. The final
concentration of the solutions was 132, 66, 33, 16.5, and
8.25𝜇g/mL. The tubes were then inoculated with the test
organisms, grown in their suitable broth at 37
∘Cf o r2 4 h
for bacteria (about 1×1 0
6 CFU/mL). each 5mL received
0.1mL of the previous inoculum and incubated at 37
∘Cf o r
24h. The lowest concentration showing no growth was taken
as the minimum inhibitory concentration (MIC). Control
experiments with DMF and uninoculated media were run
parallel to the test compounds under the same conditions.
The MIC (mg/mL) and inhibition zone diameters values are
recorded in Table 1.
4. Results and Discussion
4.1. Chemistry. The synthetic strategies adopted for the
synthesis of the intermediates and target compounds are
depicted in Scheme 1.Th es t a r t i n gm a t e r i a lc o m p o u n d2 (4-
nitrophenylferrocene) was synthesized through arylation of
ferrocene by a diazonium salt under phase transfer con-
ditions, according to the literature [31]. The reduction of
compound 2 with tin in acidic condition gives compound 3
(4-ferrocenylaniline) [32].
The urea (4a–4e) and thiourea derivatives (4f–4j)w e r e
obtained by the reaction of 4-ferrocenylaniline with the
appropriate isocyanates and isothiocyanates, respectively, in
ethanol. The sulfonamide derivatives (5a–5d) were synthe-
sized by the reaction of 4-ferrocenylaniline with the appro-
priate sulfonic acid in the presence of dicyclohexylcarbodi-
imide/dimethylaminopyridine (DCC/DMAP).
The chemical structures of the title compounds were
elucidated by
1H-NMR,
13C-NMR, and FT-IR spectra and
elemental analysis. Elemental analysis data of all products
were in good agreement with the calculated values. IR
spectra of all compounds showed all characteristic peaks.
The absence of N–H at 3500–3300cm
−1 confirmed the
formation of urea, thiourea, and sulfonamide.
1H-NMR
and
13C-NMR spectra of the synthesized compounds were
recorded in CDCl3 relative to TMS as reference. The
1H-
NMRspectrumshowedsignalsintheregionat6.69–7 .73ppm
corresponding to the aromatic phenyl protons. The benzene
ring directly attached to ferrocene contained two types of
protons which appeared as a doublet with coupling constant
of 8.4–8.6Hz. Substituted cyclopentadiene contained two
types of protons, which appeared as two singlets at 4.39–
4.48 and 4.93–5.04ppm, respectively. All five protons of
unsubstituted cyclopentadiene were chemically equivalent
and appeared in
1H-NMR spectra as singlets at 4.00–
4.04ppm. In the
1H-NMR spectra, the N–H protons of the
urea (4a–4e)a n dth i o u r ea( 5a–5e) derivatives were observed
as two separate singlets at 9.43–9.94 and 10.73-11.03ppm,
respectively. The N-H protons of the sulfonamide derivatives
(6a–6d) were observed as singlet at 11.27–11.34. In the
13C-
NMR spectra, the compounds 4a–4e showed a signal at
155.0–156.1ppm due to (C=O) of urea derivatives. Thiourea
derivatives 5a–5e showed a signal at 179.2–180.5ppm due to
(C=S).
4.2. Antimicrobial Activity. Fourteen of the newly synthe-
sized target compounds were evaluated for their in vitro
antibacterial activities at 100𝜇g/mL concentration against
Staphylococcus aureus ATCC 29213 and Bacillus subtilis
ATCC 6633 as examples of Gram-positive bacteria and
Klebsiella pneumonia ATCC13883 and Escherichia coli ATCC
25922 as examples of Gram-negative bacteria. They were
also evaluated for their in vitro antifungal potential against
Saccharomyces cerevisiae and Candida albicans NRRL Y-
477 fungal strains. Agar-diffusion method was used for the
determinationofthepreliminaryantibacterialandantifungal
activities. Ciprofloxacin and Ketoconazole were used as
reference drugs. The results were recorded for each tested
compound as the average diameter of inhibition zones (IZ)
o fb a c t e r i a lo rf u n g a lg r o w t ha r o u n dt h ed i s k si nm m .Th e
results depicted in Table 1 revealed that most of tested com-
pounds displayed variable inhibitory effects on the growth of
thetestedGram-positiveandGram-negativebacterialstrains
and also against antifungal strains.
In general, most of the urea derivatives revealed better
activity against the Gram-positive rather than the Gram-
negative bacteria. Most of sulfonamide derivatives have
superior significant antifungal potency than antibacterial
potency. It would be also noticed that compounds belonging
to the urea and thiourea groups exhibited better antibacterial
potentials than members of the sulfonamide groups. Com-
pounds 4b, 4c, 5b,a n d6b exhibited the highest potency
against tested organisms with respect to reference drugs.
Compound 4b inhibited the growth of S. aureus ATCC
29213, B. subtilis ATCC6633, and K. pneumonia ATCC13883
with inhibition zones 33, 31, and 32 mm, respectively. While
compounds 5b and 5e showed excellent activity against K.
pneumonia ATCC13883 and E. coli ATCC 25922 of Gram-
negativebacteria,alsocompounds6band6dshowedhighest
activity against S. cerevisiae and C. albicans NRRL Y-477
fungal strains.
The minimum inhibitory concentration (MIC) of the
synthesized compounds against highly inhibited organisms
is reported in Table 2.C o m p o u n d4b exhibited low MIC
(8.25𝜇g/mL) against S. aureus ATCC 29213, B. subtilis ATCC
6633, and K. pneumonia ATCC13883. On the other hand,
compound 4b revealed high MIC (132𝜇g/mL) against C.
albicans NRRL Y-477 fungal strains. Compounds 5b and 5e
showed MIC 8.25 𝜇g/mL against K. pneumonia ATCC13883
andE.coliATCC25922ofGram-negativebacteria.Addition-
ally, compounds 5d, 6b, and 6d exhibited MIC 8.25𝜇g/mL
against S. cerevisiae, and also 6a and 6d showed MIC
8.25𝜇g/mL against C. albicans NRRL Y-477 fungal strains.Journal of Chemistry 5
Table 1: Antimicrobial activity expressed as inhibition diameter zones in millimeters (mm) of chemical compounds against the pathological
strains based on well diffusion assay.
Compound
Zone of inhibition (mm)
Bacteria Fungi
Gram-positive Gram-negative S. cerevisiae C. albicans
S. aureus B. subtilis K. pneumoniae E. coli
4a 22 18 18 14 19 16
4b 33 31 32 27 16 15
4c 30 32 27 32 20 21
4d 20 19 24 27 18 16
4e 23 18 18 19 14 19
5a 28 26 24 24 26 29
5b 25 27 30 31 24 28
5c 24 28 28 24 21 32
5d 23 30 26 28 29 26
5e 26 22 32 33 24 26
6a 24 28 24 25 26 30
6b 22 25 29 28 32 34
6c 28 24 17 22 24 18
6d 22 23 26 28 30 30
Ciprofloxacin 30 30 29 24 NT NT
Ketoconazole NT NT NT NT 30 31
The experiment was carried out in triplicate, and the average zone of inhibition was calculated.
NT: not tested.
Table 2: Minimum inhibitory concentration (𝜇g/mL) against the pathological strains based on twofold serial dilution technique.
Compound
MIC in 𝜇g/mL
Bacteria Fungi
Gram-positive Gram-negative S. cerevisiae C. albicans
S. aureus B. subtilis K. pneumoniae E. coli
4a 33 66 66 132 66 132
4b 8.25 8.25 8.25 16.5 132 132
4c 16.5 8.25 16.5 8.25 66 66
4d 66 33 16.5 16.5 66 132
4e 33 66 66 66 132 66
5a 16.5 16.5 16.5 33 16.5 8.25
5b 33 16.5 8.25 8.25 33 16.5
5c 33 16.5 16.5 33 16.5 8.25
5d 33 8.25 33 16.5 8.25 33
5e 16.5 33 8.25 8.25 33 33
6a 33 16.5 33 33 16.5 8.25
6b 33 33 16.5 16.5 8.25 16.5
6c 16.5 33 66 33 33 66
6d 33 66 33 16.5 8.25 8.25
Ciprofloxacin 8.25 8.25 8.25 16.5 NT NT
Ketoconazole NT NT NT NT 8.25 8.25
NT: not tested.
5. Conclusion
In conclusion, the objective of the present study was to
synthesizeandinvestigatetheantimicrobialactivitiesofsome
novel ferrocene derivatives carrying urea, thiourea, and sul-
fonamide groups with the hope of discovering new structure
leads serving as potent antimicrobial agents. Amongst the
tested compounds, 4b, 4c, 5b,a n d6b displayed excellent6 Journal of Chemistry
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Scheme 1: Synthesis of ferrocene derivatives carrying urea, thiourea and sulfonamide moieties.
antimicrobial activity. These preliminary results are bene-
ficial for further studies in developing new urea, thiourea,
and sulfamide substituted ferrocene derivatives as potential
antimicrobial agents.
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